- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Eosinophilic asthma
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Benralizumab – March 2020
Benralizumab: Injection 30 mg in 1 ml pre-filled pen; Fasenra Pen®
Last updated
3 July 2020